Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alcon Inc. stock logo
ALC
Alcon
$94.83
-1.0%
$91.96
$80.48
$101.10
$46.77B1.061.07 million shs2.07 million shs
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$11.91
+5.6%
$13.37
$10.45
$21.69
$4.21B0.58651,866 shs1.12 million shs
ICON Public Limited stock logo
ICLR
ICON Public
$140.22
+4.7%
$159.00
$133.28
$347.72
$11.32B1.231.01 million shs1.72 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alcon Inc. stock logo
ALC
Alcon
0.00%-2.60%+6.90%+7.32%+16.85%
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.00%-2.09%-1.40%-30.87%-27.13%
ICON Public Limited stock logo
ICLR
ICON Public
0.00%-6.30%-7.00%-29.81%-57.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alcon Inc. stock logo
ALC
Alcon
2.9436 of 5 stars
3.43.01.70.02.30.81.3
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
3.9308 of 5 stars
4.12.00.00.02.60.03.8
ICON Public Limited stock logo
ICLR
ICON Public
4.5371 of 5 stars
4.35.00.00.01.83.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alcon Inc. stock logo
ALC
Alcon
2.71
Moderate Buy$106.2212.01% Upside
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
2.25
Hold$15.5030.20% Upside
ICON Public Limited stock logo
ICLR
ICON Public
2.60
Moderate Buy$215.3353.57% Upside

Current Analyst Ratings Breakdown

Latest BLCO, ALC, and ICLR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/2/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
5/2/2025
ICON Public Limited stock logo
ICLR
ICON Public
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$165.00 ➝ $155.00
5/2/2025
ICON Public Limited stock logo
ICLR
ICON Public
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $160.00
5/2/2025
ICON Public Limited stock logo
ICLR
ICON Public
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$192.00 ➝ $160.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $13.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $12.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $15.50
4/29/2025
ICON Public Limited stock logo
ICLR
ICON Public
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$265.00 ➝ $150.00
4/24/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/14/2025
ICON Public Limited stock logo
ICLR
ICON Public
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$254.00 ➝ $157.00
(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alcon Inc. stock logo
ALC
Alcon
$9.91B4.72$5.50 per share17.23$41.81 per share2.27
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$4.83B0.87$1.42 per share8.41$18.57 per share0.64
ICON Public Limited stock logo
ICLR
ICON Public
$8.19B1.38$13.63 per share10.29$115.44 per share1.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alcon Inc. stock logo
ALC
Alcon
$974M$2.0540.5328.822.2911.89%7.17%5.03%5/13/2025 (Estimated)
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A12.400.85-6.62%3.35%1.66%7/30/2025 (Estimated)
ICON Public Limited stock logo
ICLR
ICON Public
$612.34M$9.1814.719.171.869.56%11.81%6.65%7/23/2025 (Estimated)

Latest BLCO, ALC, and ICLR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Alcon Inc. stock logo
ALC
Alcon
$0.76N/AN/AN/A$2.52 billionN/A
4/30/2025Q1 2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
4/30/2025Q1 2025
ICON Public Limited stock logo
ICLR
ICON Public
$3.17$3.19+$0.02$1.90$2.03 billion$2.00 billion
2/25/2025Q4 2024
Alcon Inc. stock logo
ALC
Alcon
$0.70$0.72+$0.02$0.57$2.47 billion$2.48 billion
2/19/2025Q4 2024
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.23$0.25+$0.02-$0.01$1.26 billion$1.28 billion
2/19/2025Q4 2024
ICON Public Limited stock logo
ICLR
ICON Public
$3.41$3.42+$0.01$3.16$2.04 billion$2.04 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alcon Inc. stock logo
ALC
Alcon
$0.260.27%+33.89%12.68%4 Years
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
ICON Public Limited stock logo
ICLR
ICON Public
N/AN/AN/AN/AN/A

Latest BLCO, ALC, and ICLR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/7/2025
Alcon Inc. stock logo
ALC
Alcon
annual$0.32700.3%5/14/20255/14/20255/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alcon Inc. stock logo
ALC
Alcon
0.21
2.57
1.60
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.72
1.60
1.01
ICON Public Limited stock logo
ICLR
ICON Public
0.36
1.26
1.34

Institutional Ownership

CompanyInstitutional Ownership
Alcon Inc. stock logo
ALC
Alcon
53.86%
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
11.07%
ICON Public Limited stock logo
ICLR
ICON Public
95.61%

Insider Ownership

CompanyInsider Ownership
Alcon Inc. stock logo
ALC
Alcon
1.52%
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.76%
ICON Public Limited stock logo
ICLR
ICON Public
44.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alcon Inc. stock logo
ALC
Alcon
25,200493.24 millionN/AOptionable
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
12,500353.37 million351.94 millionOptionable
ICON Public Limited stock logo
ICLR
ICON Public
41,10080.76 million46.20 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alcon stock logo

Alcon NYSE:ALC

$94.83 -0.92 (-0.96%)
Closing price 03:59 PM Eastern
Extended Trading
$94.79 -0.04 (-0.04%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$11.90 +0.64 (+5.63%)
Closing price 03:59 PM Eastern
Extended Trading
$11.86 -0.05 (-0.42%)
As of 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

ICON Public stock logo

ICON Public NASDAQ:ICLR

$140.22 +6.26 (+4.67%)
Closing price 04:00 PM Eastern
Extended Trading
$141.22 +1.00 (+0.71%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.